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ABSTRACT
Liquid–liquid phase separation (LLPS) of proteins
and RNAs has emerged as the driving force underly-
ing the formation of membrane-less organelles. Such
biomolecular condensates have various biological
functions and have been linked to disease. The pro-
tein Fused in Sarcoma (FUS) undergoes LLPS and
mutations in FUS have been causally linked to the
motor neuron disease Amyotrophic Lateral Sclero-
sis (ALS-FUS). LLPS followed by aggregation of cy-
toplasmic FUS has been proposed to be a crucial
disease mechanism. However, it is currently unclear
how LLPS impacts the behaviour of FUS in cells, e.g.
its interactome. Hence, we developed a method al-
lowing for the purification of LLPS FUS-containing
droplets from cell lysates. We observe substantial
alterations in the interactome, depending on its bio-
physical state. While non-LLPS FUS interacts mainly
with factors involved in pre-mRNA processing, LLPS
FUS predominantly binds to proteins involved in
chromatin remodelling and DNA damage repair. In-
terestingly, also mitochondrial factors are strongly
enriched with LLPS FUS, providing a potential ex-
planation for the observed changes in mitochondrial
gene expression in mouse models of ALS-FUS. In
summary, we present a methodology to investigate
the interactomes of phase separating proteins and
provide evidence that LLPS shapes the FUS interac-
tome with implications for function and disease.
INTRODUCTION
The biophysical process of liquid–liquid phase separation
(LLPS) has drawn considerable attention over the last cou-
ple of years. Indeed, the regulators as well as the biophys-
ical driving forces of LLPS are only just beginning to be
understood. LLPS was not only reported to be important
for the formation of various membraneless organelles such
as nucleoli, P-bodies and stress granules, but also has been
implicated in various diseases (1–3). One of the best stud-
ied proteins that undergoes LLPS in vitro and in vivo is
Fused in Sarcoma (FUS) (4–10). FUS is a ubiquitously ex-
pressed RNA-binding protein that has been implicated in
diverse RNA metabolic pathways, such as transcription,
pre-mRNA splicing and miRNA processing (11–16). In
2009, mutations in FUS were shown to be causative for
Amyotrophic Lateral Sclerosis (ALS) (17,18). ALS is the
most common motor neuron disease in human adults and
is characterized by a progressive loss of upper and lower
motor neurons, causing paralysis and ultimately leading
to death (19). The most frequent ALS-causing mutations
in FUS disrupt its C-terminal nuclear localization signal
(NLS), leading to cytoplasmic mislocalization and aggre-
gation of FUS in neurons and glial cells of affected indi-
viduals, a pathological hallmark of FUS-ALS (20,21). Sev-
eral recently published mouse models indicate a toxic gain
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of FUS function in the cytoplasm (22–24). Noteworthy, re-
cruitment of FUS into phase separated RNP granules, e.g.
stress granules, followed by aggregation has been proposed
to drive disease (25,26).
Due to the current lack of tools to study membraneless
organelles (27), LLPS-dependent FUS interactions are un-
known and it is unclear how ALS-linked mutant FUS ex-
erts its toxic function(s). Furthermore, it is also unknown
if and how phase separation contributes to FUS function.
Aiming to better understand the functional consequences
of FUS phase separation and to identify FUS interactors
under LLPS conditions, we developed a method that allows
for the purification of phase separated FUS together with
its associated proteins and RNAs, and compared these in-
teractors to FUS interactors that were purified under non-
LLPS conditions. We observed distinct interaction patterns
depending on the biophysical state of FUS. Whereas FUS
interacts predominantly with factors involved in RNA pro-
cessing under non-LLPS conditions, phase separated FUS
preferably interacts with proteins involved in chromatin re-
modeling, DNA damage response and proteins with func-
tions in mitochondria. Furthermore, our data suggest that
LLPS in different cellular compartments serves different
functions. While phase separation-deficient FUS loses its
association with chromatin and fails to autoregulate FUS
expression, both LLPS-deficient and proficient ALS-linked
mutant FUS affect cell viability to the same extent. Taken
together, our findings indicate that LLPS is essential for
some but not all physiological functions of FUS and LLPS
may not be necessary for the gain-of-function toxicity of cy-
toplasmic mislocalized FUS. In summary, our method pro-
vides new insights into how LLPS affects FUS interaction
partners and function. Notably, this method should be ap-
plicable to other proteins that undergo LLPS and allows to
gain first insights into the role of LLPS in protein function
and interactions.
MATERIALS AND METHODS
Oligonucleotides, plasmids and antibodies
Oligonucleotides, plasmids and antibodies are described in
the Supplementary Information.
Cell culture
HeLa and HEK293T cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) containing 10% fe-
tal calf serum (FCS), penicillin (100 U/l) and strep-
tomycin (100 g/ml)) at 37◦C and 5% CO2. Cells were
transfected using Dogtor (OZ Biosciences) for all ex-
periments except for cytoplasmic/mitochondrial (mem-
brane), soluble/insoluble fractionation experiments and
transfections of HEK293T cells prior to stress fol-
lowed by immunofluorescence. For these experiments,
cells were transfected using TransIT-LT1 (Mirus). More-
over, for analysis of FUS stress granule localization af-
ter arsenite stress in HeLa cells, MTT assays and for
the E1A minigene reporter assays, Lipofectamine 2000
(Thermo Fisher) was used according to the manufacturer’s
instructions.
Generation of cell lysates for droplet purification and eGFP
co-immunoprecipitation
30 g plasmid coding for eGFP-GSG15-FUS or 15 g
plasmid coding for FLAG-eGFP, respectively were tran-
siently transfected into 40–50% confluent HEK293T cells in
a T300 flask using Dogtor according to the manufacturer’s
instructions. For the control experiment using the soluble
GB1-TwinStrep-RFP as internal marker for global protein
aggregation, 40 g pcDNA6F-eGFP-FUS P525L and 10
g pcDNA3.1-GB1-TwinStrep-RFP were transfected us-
ing Dogtor. The medium was replaced 24 h after trans-
fection. 48 h after transfection, the cells were harvested
by flushing with ice cold medium. Cells were pelleted at
4◦C at 200 g for 5 min. After removal of the supernatant,
the cells were washed with ice cold PBS. Thereafter, cells
were pelleted at 4◦C for 3 min at 1500 g. PBS was re-
moved and the cells were snap frozen in liquid nitrogen
and stored at –80◦C until usage. The pellet was thawed
on ice and re-suspended in the approximate volume of the
cell pellet (400 l) lysis buffer (75 mM HEPES pH7.3, 100
mM KOAc, 0.5 mM DTT, 0.5% NP40, 1:5000 Antifoam
B, 10 l/ml lysis buffer protease inhibitor, 10 l/ml ly-
sis buffer RNase inhibitor) and transferred to a 1.5 ml
Eppendorf tube. To increase lysis efficiency, the cells were
passed 5× through a 25 G 5/8 needle. The lysate was subse-
quently used to isolate FUS droplets or to perform an eGFP
co-immunoprecipitation.
Purification of FUS-containing droplets
To increase the formation of LLPS FUS droplets, the vol-
ume of the lysate was reduced to approximately half of the
initial volume in a speedvac (to reach the approximate vol-
ume of the initial cell pellet). To reduce time in the speedvac,
samples were split into several smaller samples of approx.
150 l. To monitor droplet formation, a drop of the lysate
was placed on a standard microscopy glass slide, covered
with a coverslip and FUS droplets were visualized using a
fluorescence microscope. Subsequently, 30 l concentrated
lysate were transferred to a new 1.5 ml Eppendorf tube and
droplets were stabilized by adding 0.3 l 10% formaldehyde
(final conc. 0.1%). The lysate was mixed by vortexing and
incubated for 8 min at room temperature. Remaining cross-
linker was quenched through the addition of 1 l 1 M TRIS
pH7.3 and vortexing. The sample was thereafter stored on
ice until droplets were sorted by fluorescence activated par-
ticle sorting (FAPS). Right before sorting, 300 l PBS was
added to the lysate and the sample was passed through a
40 m cell strainer (to get rid of aggregates which could
clog the sorter). Droplets were sorted into PBS according to
eGFP-fluorescence and side scatter (SSC) on a FACS ARIA
(BD Biosciences). Sorted droplets were stored at – 80◦C un-
til further processing. Before protein or RNA isolation, the
droplets were pelleted by centrifugation at 4◦C at 16 000 g
for 15 min. The droplet-pellet was washed with 1 ml PBS.
The wash was repeated one more time. Between washes, the
droplets were centrifuged for 15 min 4◦C at 16 000 g. Af-
ter removal of the PBS, 150 000 droplets (sorted events)
were either re-suspended in 50 l 1× LDS-loading buffer
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Fisher) diluted to 1× supplemented with 50 mM DTT) for
protein elution or in 50 l RNA-sample buffer (50 mM Tris
pH7.0, 5 mM EDTA, 1% SDS, 10 mM DTT) for subse-
quent RNA isolation. Pictures and video of cell lysates and
droplets were acquired using a wide-field fluorescence Leica
DMI6000 B microscope.
eGFP nanobodies and coupling to magnetic beads
Plasmids encoding for His-tagged anti-GFP nanobodies
(clones LaG-9, LaG-16 and LaG-24) were obtained un-
der the MTA from Michael P Rout laboratory (Rockefeller
University, New York, USA). All three constructs were ex-
pressed in ArticExpress (DE3) cells (Agilent) and purified
using Ni-NTA resin as described (28). Purified anti-GFP
nanobodies were coupled to magnetic beads (Dynabeads
M-270 Epoxy, Invitrogen) accordingly to manufacturer’s in-
struction. The coupling mixture contained 20 g of purified
nanobody per 1 mg of beads. The coupling reaction was car-
ried out (separately for each clone) with rotation, at 37◦C
for 20 h. Anti-GFP nanobodies coupled to magnetic beads
were re-suspended in 50% glycerol/PBS (2 ml per 300 mg
beads) and stored at –20◦C. In order to increase GFP bind-
ing efficiency, beads coupled to three different clones were
mixed together in 1:1:1 ratio.
eGFP co-immunoprecipitation
20 l GFP nanobodies coupled to magnetic beads were
transferred to 1 ml lysis buffer (75 mM HEPES pH7.3, 100
mM KOAc, 0.5 mM DTT, 0.5% NP40, 1:5000 Antifoam B,
10 l/ml lysis buffer protease inhibitor, 10 l/ml lysis buffer
RNase inhibitor). Lysis buffer was removed and washed
again with 1 ml lysis buffer. After removal of the lysis buffer,
the beads were re-suspended in 100 l lysis buffer and added
to 400 l previously prepared cell lysate. The beads were in-
cubated for 3 h at 4◦C head over tail on a rotor. Thereafter,
the supernatant was removed and the beads were washed
5 × 5 min in 1 ml of 2× lysis buffer at 4◦C head over tail on
a rotor. The first wash step contained protease and RNase
inhibitors. After the last wash step, the beads were splitted
in two parts and either re-suspended in 1 ml TRIZOL for
RNA isolation or 50 l 1× LDS-loading buffer for protein
elution.
Mass spectrometry
The formaldehyde crosslink was reversed, eGFP-fusion
proteins were eluted from the beads by boiling the sam-
ples for 15 min at 95◦C in LDS-loading buffer. Cell lysates
mixed with equal volumes of 2× LDS-loading buffer and
boiled for 15 min at 95◦C served as input samples. To pre-
pare the samples (each experimental condition in biological
triplicates) for mass spectrometry, samples were run 1 cm
into a 12% Bis-Tris Plus gel (Invitrogen). 150 000 droplets
(sorted events) and 3/5 of the eGFP co-IP, respectively were
loaded. The gel was subsequently washed 5 × 5 min in ul-
trapure water, 10 min in 0.1 M HCl and Coomassie stained
for 2 h (0.12% (w/v) Coomassie G-250, 10% H3PO4 (v/v),
10% (w/v) NH4OAc, 20% MeOH (v/v)) to visualize pro-
teins. The gel was de-stained for 8 × 30 min in ultrapure
water. To prepare gel pieces for mass spectrometry, the gel
was cut, using a clean scalpel, into approx. 0.25 cm hori-
zontal bands. The bands were further cut into cubes of ∼1–
3 mm3 and transferred to a 1.5 ml Eppendorf tube. Sam-
ples were stored at 4◦C in 20% EtOH before reduction and
alkylation. Samples were analyzed in a random order to
avoid chromatographic batch effects. The gel pieces were re-
duced, alkylated and digested by trypsin as described else-
where (29). The digests were analyzed by nano-liquid chro-
matography tandem masspectrometry (nLC-MS/MS) (Ea-
syLC 1000 nanoflow-UPLC coupled to a QExactive HF
mass spectrometer, ThermoFisher Scientific) with one injec-
tion of 5 l digests. Peptides were trapped on a Precolumn
(C18 PepMap100, 5 m, 100 Å, 300 m × 5 mm, Thermo
Fisher Scientific, Reinach, Switzerland) and separated by
backflush on a C18 column (3 m, 100 Å, 75 m × 15 cm,
C18, Nikkyo Technos, Tokyo, Japan) by applying a 40-min
gradient of 5% acetonitrile to 40% in water, 0.1% formic
acid, at a flow rate of 350 nl/min. The Full Scan method
was set with resolution at 60 000 with an automatic gain
control (AGC) target of 1E06 and maximum ion injection
time of 50 ms. The data-dependent method for precursor
ion fragmentation was applied with the following settings:
resolution 15 000, AGC of 1E05, maximum ion time of 110
ms, isolation width of 1.6 m/z, collision energy 27, under
fill ratio 1%, charge exclusion of unassigned and 1+ ions,
and peptide match preferred, respectively. Spectra interpre-
tation was performed with MaxQuant/Andromeda version
1.5.4.1 searching against the forward and reversed Swis-
sProt Homo Sapiens protein database (Release 2017 12)
using fixed modification of carbamidomethylation on Cys,
and variable modifications of oxidation on Met, deamida-
tion on Asn /Gln, and acetylation on protein N-term. Mass
error tolerance for parent ions was set to 10 ppm, fragment
ion tolerance to 20 ppm, and full trypsin cleavage speci-
ficity with three missed cleavages were allowed. Based on
reversed database matches a 1% false discovery rate (FDR)
was set for acceptance of peptide spectrum matches (PSM),
peptides, and proteins. Relative protein abundance was cal-
culated as described elsewhere (30). In brief, contaminant
proteins such as keratins and trypsin were removed and the
remaining protein’s iBAQ values were each divided by the
sum of all non-contaminant iBAQ values. Relative iBAQ
values were used to determine fold changes and P-values
using Student’s t-test and adjusted P-values (FDR) between
experimental conditions. To be assigned to the LLPS inter-
actome of FUS, proteins purified from FUS droplets had
to be enriched >2-fold compared to the input with a FDR
<0.05. To be assigned to the non-LLPS interactome, pro-
teins co-IPed with FUS had to be enriched > 2-fold com-
pared to the input as well as to the control IP (FLAG-
eGFP), with a FDR <0.05 for both. The relative contribu-
tion of previously identified FUS interactors (12,31–36) to
the FUS interactors identified in this study was calculates
as follows: The sum of all FUS interactors that were identi-
fied in this study and in at least one of the above mentioned
studies was divided by the sum of all FUS interactors iden-








niversitaetsbibliothek Bern user on 06 August 2021
7716 Nucleic Acids Research, 2021, Vol. 49, No. 13
RNA isolation and RNA deep sequencing
To isolate RNA from the droplets, the formaldehyde
crosslink was reversed through incubation of the droplets
in RNA-sample buffer (50 mM Tris pH 7.0, 5 mM EDTA,
1% SDS, 10 mM DTT) for 40 min at 70◦C. After cooling
of the sample on ice for 5 min, 1 ml TRIZOL was added.
RNA was isolated from TRIZOL according to the man-
ufacturer’s instructions. Quality and quantity of RNA
was analyzed with an Agilent 2100 Bioanalyzer (Agilent
Technologies). Total RNA isolated from transiently trans-
fected cells served as input RNA. Total RNA isolated from
droplets, from the co-IP and input RNA (in biological
triplicates for each sample) were ribodepleted using the
RiboMinus™ Transcriptome Isolation Kit (Invitrogen,
K155004) before library preparation according to the
manufacturer’s manual. Libraries were prepared using
the strand-specific Illumina TruSeq Stranded Total RNA
kit (Part # 15031048 Rev. E). Total RNA libraries were
sequenced on the Illumina HiSeQ3000 platform using 100
bp single-end sequencing cycles. Adapters and low quality
bases were trimmed from reads using TrimGalore v0.4.4
https://github.com/FelixKrueger/TrimGalore (37,38).
Reads were then mapped using Salmon v0.8.2 (39) to
the human cDNA and non-coding RNA transcriptome,
ENSEMBL version 38.90. Transcripts per million (TPM)
were imported into R using tximport v1.4.0 (40), and
differential gene expression analysis performed using
edgeR v3.18.1 (41). Transcript lengths were included as
an offset in modelling, and transcript length scaled TPMs
were used for calculating average log2(TPM). RNAs with
>2-fold change to the input with a FDR <0.001 were con-
sidered as significantly enriched over the input. To assess
relative abundances of different RNA biotypes, several
ENSEMBL gene biotypes were summarized in groups
(pseudogenes include: ‘transcribed unitary pseudogene’,
‘unprocessed pseudogene’, ‘processed pseudogene’,
‘transcribed unprocessed pseudogene’, ‘polymor-
phic pseudogene’, ‘transcribed processed pseudogene’,
‘IG V pseudogene’, ‘unitary pseudogene’,
‘TR V pseudogene’, ‘TR J pseudogene’, ‘IG C pseudogene’,
‘IG J pseudogene’, ‘translated processed pseudogene’,
‘pseudogene’, ‘IG pseudogene’. lncRNAs in-
clude: ‘antisense RNA’, ‘lincRNA’, ‘sense intronic’,
‘sense overlapping’, ‘bidirectional promoter lncRNA’,
‘3prime overlapping ncRNA’, ‘macro lncRNA’.
other ncRNA include: ‘processed transcript’, ‘misc RNA’,
‘ribozyme’, ‘sRNA’, ‘non coding’. other include:
‘TR V gene’, ‘IG V gene’, ‘IG C gene’, ‘IG J gene’,
‘TR J gene’, ‘TR C gene’, ‘IG D gene’ ‘TR D gene’. 7SL
and 7SK genes were excluded from the above groups to
form each a separate group.
STRING and gene ontology (GO) enrichment analysis
STRING (42) analysis was performed using the multi pro-
tein search function using default options. The ‘confidence’
option was chosen to indicate strength of data support for
each interaction. In addition, GO terms indicated in the fig-
ure legends were highlighted. GO term analysis was per-
formed using the WEB-based GEne SeT AnaLysis Toolkit
(WebGestalt) (43) using default settings with the follow-
ing options: organism of interest: Homo sapiens; method
of interest: over-representation analysis (ORA); functional
database: geneontology, biological process noRedundant.
For GO term analysis of genes identified by mass spectrom-
etry, the Reference Set ‘genome protein-coding’ was used.
For GO term analysis of genes identified by RNAseq, the
Reference Set ‘genome’ was used.
Flow cytometry to analyze formation of FUS-droplets
To analyze FUS droplets by flow cytometry, FUS droplets
were prepared as described above. Droplets were analyzed
on a LSR II SORP H274 (BD Biosciences) and generated
data was processed using FlowJo version 10.
Soluble versus insoluble fractionations
60–80% confluent HEK293T cells in T25 flasks were har-
vested using Trypsin/EDTA and washed once with ice cold
PBS. The cells were lysed in RIPA buffer (Thermo Fisher,
89900) containing 1× Halt™ Protease Inhibitor Cocktail
(Thermo Fisher, 78429) for 20 min on ice with occasional
vortexing. Samples were centrifuged for 15 min at 16 000
g at 4◦C and the supernatant was subsequently mixed with
equal volumes of 2× LDS-loading buffer (NuPAGE™ LDS
Sample Buffer (4×) (NP0007, Thermo Fisher) diluted to
2× supplemented with 100 mM DTT) and boiled for 5 min
at 95◦C (soluble fraction). The insoluble pellet was washed
twice with PBS and thereafter incubated in insoluble buffer
(50 mM Tris pH7.5, 200 mM NaCl, 2 mM KCl, 1 mM
EDTA, 0.5% Glycerol, 100 mM Urea, 1× Halt™ Protease
Inhibitor Cocktail) for 1 h at 37◦C at 1400 rpm. The sample
was centrifuged for 5 min at 16 000 g and the supernatant
was subsequently mixed with equal volumes of 2× LDS-
loading buffer and boiled for 5 min at 95◦C (insoluble frac-
tion).
Cytoplasmic/nucleoplasmic vs chromatin fractionation
40–60% confluent HEK293T cells on 10 cm plates were
transfected with 3 g expression construct (FLAG-
FUS, FLAG-FUS PLD27YS or FLAG-FUS PLD27YS
SV40NLS respectively) using Dogtor (OZ Biosciences) ac-
cording to the manufacturer’s instructions. The medium
was changed 24 h after transfection and cells were har-
vested 48 h after transfection using a cell scraper. Cells were
transferred to a 15 ml Falcon tube and spun for 5 min at
200 g at 4◦C. After removal of the supernatant, cells were
washed with 1 ml ice-cold PBS and transferred to a 1.5 ml
Eppendorf tubed and pelleted for 3 min at 300 g at 4◦C.
Cells were re-suspended in 1 ml buffer A (10 mM HEPES
pH7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10%
glycerol, 0.1% Triton-X-100, 1 mM DTT and 1X Halt™
Protease Inhibitor Cocktail) and incubated for 5 min on
ice. The suspension was centrifuged for 4 min at 1300 g at
4◦C and the supernatant (cytoplasmic fraction) was trans-
ferred to a new Eppendorf tube. The pellet was washed
once with buffer A. Thereafter, the pellet was re-suspended
in 1 ml buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM
DTT and 1× Halt™ Protease Inhibitor Cocktail) and in-
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for 4 min at 1700 g at 4◦C and the supernatant (nucleoplas-
mic fraction) was combined with the cytoplasmic fraction
(forming the cytoplasmic/nucleoplasmic fraction). The pel-
let was washed once with buffer B. Then, the pellet was re-
suspended in 1 ml buffer C (50 mM Tris pH 7.5, 200 mM
NaCl, 2 mM KCl, 1 mM EDTA, 0.5% glycerol, 100 mM
urea and 1× Halt™ Protease Inhibitor Cocktail) and in-
cubated in a heat block for 1 h at 37◦C at 1400 rpm. Af-
ter centrifugation for 5 min at 16 000 g, the supernatant
(chromatin associated proteins) was transferred to a new
Eppendorf tube. The pellet was subsequently washed with
ultrapure water and buffer D (1 mM MgCl2, 1 mM CaCl2,
1× Halt™ Protease Inhibitor Cocktail). The pellet was then
re-suspended in 884 l buffer E (50 mM Tris pH 8.0, 10 mM
NaCl, 1 mM MnSO4, 0.25 U/ml Cyanase (18542, Serva)
and 1× Halt™ Protease Inhibitor Cocktail) and incubated
for 15 min at 30◦C at 600 rpm. Thereafter, NaCl was in-
creased to 600 mM through addition of 116 l of 5 M NaCl.
The samples were incubated for another 15 min at 37◦C at
1400 rpm. After centrifugation for 5 min at 16 000 g, the
supernatant (chromatin) was combined with the chromatin
associated fraction (forming chromatin fraction). Fractions
were supplemented with equal amounts of 2× LDS-loading
buffer and boiled for 5 min at 95◦C.
Cell viability assay – MTT
Two days prior to the experiment, HeLa WT were
transiently transfected with either empty Flag vector,
pcDNA6F-FUS P525L PLD27YS or pcDNA6F-FUS
PLD27YS P525L constructs using Lipofectamine 2000
diluted in OptiMEM. After 18 h, cells were counted,
and 8 × 103 cells were seeded per well in 96-wells plates.
Cells were allowed to attach for at least 24 h. The cells
were then incubated for 4 h with a solution of MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; Sigma-Aldrich) to a final concentration of
50 g/ml. The solution was then removed, and cells were
lysed in 100 l DMSO before reading the absorbance
(570 nm) using a multiwell VictorX spectrophotometer
(Perkin-Elmer).
To assess the efficiency of transfected cells, some cells
were fixed in 2% PFA and then immunostained for Flag.
As the cells were in suspension, 3 min centrifugation at
300 g were done between each step. In brief, fixed cells were
permeabilized in 0.1% Triton for 5 min and then washed
twice in wash buffer (0.2% BSA in PBS). Cells were blocked
in 20% FBS and 0.05% Tween20 diluted in PBS for 30
min, followed by two washes. Cells were incubated for 30
min with primary antibody mouse anti-Flag (1:150, Sigma-
Aldrich F1804) diluted in wash buffer. After three washes,
cells were incubated for 30 min with Alexa Fluor 488 goat
anti-mouse (1:2000, Invitrogen A-11001). Cells were then
washed twice with PBS and finally resuspended in 300 l
of PBS. Positive cells were quantified using a Beckman
Cytoflex FACS apparatus. IBM SPSS version 26 software
was used for statistical analysis. MTT data was analysed
using one-way ANOVA. When appropriated, analysis was
followed by Bonferroni post-hoc test for group-wise com-
parisons. Values of P < 0.05 were considered statistically
significant.
Immunofluorescence
HEK293T cells were grown on poly-D-lysine (Sigma
Aldrich, A-003-E) coated eight-well slides (PEZGS0816,
Milipore) for immunostaining experiments. For all exper-
iments except for data presented in Figure 5E (see below),
HeLa cells were grown in uncoated 8-well slides. Cells were
fixed for 20 min in 4% PFA in PBS and subsequently washed
3× with PBS. For permeabilization and blocking, cells were
incubated for 45 min in 0.5% Triton, 6% BSA in TBS at
room temperature. Primary antibodies were diluted in 0.1%
Triton, 6% BSA in TBS (TBS +/+) and added to the cells
overnight at 4◦C. Thereafter, cells were washed 3× with TBS
+/+ and incubated for 1 h at room temperature with sec-
ondary antibodies diluted in TBS +/+. Cells were counter-
stained with DAPI (100 ng/ml in PBS) for 10 min at room
temperature. After two additional wash steps in PBS, cells
were mounted with Vecashield Hardset mounting medium
(H-1400, Vector Laboratories). If indicated, the follow-
ing stresses were applied prior to fixation. Arsenic stress:
0.5 mM sodium(meta)arsenite (NaAsO2) (S7400, Sigma
Aldrich) for 1 h. Sorbitol stress: 0.4 M D-sorbitol (S1876,
Sigma Aldrich). Slides were analyzed using a wide-field flu-
orescence Leica DMI6000 B microscope or a wide-field Ti-
E epifluorescence microscope, Nikon.
For analysis of FUS stress granule localization after
arsenite stress in Figure 5E, HeLa cells were seeded on
coverslips in 24-well tissue culture plates and were trans-
fected with 0.4 g Flag-FUS-R495X or Flag-FUS R495X-
PLD27YS using Lipofectamine 2000 according to the
manufacturer’s instructions. Twenty four hours later, cells
were stressed with 0.5 mM Sodium (meta)arsenite (Sigma
S71287) for 1 h and processed for immunocytochemistry as
previously described (44), using anti-FLAG and anti-TIA-1
antibodies. Confocal images were obtained with an inverted
laser scanning confocal microscope (Zeiss confocal 710)
with a 63x/1.4 N.A. oil immersion lens. For quantification,
the number of cells with TIA-1 positive SGs was counted
in three independent experiments, analyzing at least 50 cells
per experimental condition and replicate.
Immunoblotting
Proteins from spinal cord of 9-month-old wild type and
heterozygous 14 mice were generated as previously de-
scribed (24). Protein lysates in LDS-loading buffer were sep-
arated on a NuPAGE 4–12% Bis–Tris Midi Gel (WG1403A
or WG1402BOX, Thermo Fisher) and transferred on a ni-
trocellulose membrane using the iBlot Gel Transfer System
(Thermo Fisher) according to the manufacturer’s instruc-
tions. For analysis of SMARCA4 and SMARCA5, proteins
were separated on a NuPAGE™ 3–8% Tris-Acetate Protein
Gel (EA0375BOX, Thermo Fisher) and transferred on a
nitrocellulose membrane using the iBlot™ 2 Gel Transfer
Device (Thermo Fisher). Membranes were blocked in 2%
BSA in in 0.1% Tween in Tris-buffered saline (TBST). Mem-
branes were incubated with primary antibodies diluted in
TBST for 2 h at room temperature. After 5 × 5 min wash
steps in TBST, membranes were incubated with secondary
antibodies in TBST for 1 h at room temperature. For im-
munodetection of SMARCA4 and SMARCA5, the Super-
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was used according to the manufacturer’s instructions. To
measure total protein levels from spinal cord lysates of
mice, the REVERT™ Total Protein Stain Kit (926-11015,
LI-COR) was used according to the manufacturer’s instruc-
tions. The washed membranes were analyzed and signal in-
tensity was determined (if required for the respective ex-
periment) using the Odyssey Infrared Imaging System (LI-
COR). Statistical significance of immunoblotting results
was determined by paired t-test.
FUS autoregulation, SCN4A minigene and E1A minigene re-
porter assay
To assess FUS autoregulation, 80% confluent HeLa cells
in six wells were transfected with either 500 ng mock plas-
mid (control condition), pcDNA6F-FUS, pcDNA6F-FUS
PLD27YS or pcDNA6F-FUS PLD27YS SV40NLS respec-
tively. Twenty-four hours after transfection, cells were split
into two wells of a 6-well plate. Seventy-two hours after
transfection, cells were harvested (one-well into TRIZOL
for RNA isolation, one well into 100 l RIPA buffer con-
taining 1× Halt™ Protease Inhibitor Cocktail. Before subse-
quent western blotting, the lysate was incubated for 20 min
on ice, spun for 15 min at 4◦C at 16 000 g and the super-
natant was subsequently transferred to a new Eppendorf
tube containing equal amount of 2X LDS-loading buffer
and boiled for 5 min at 95◦C.
For the SCN4A minigene reporter assay, 80% confluent
HeLa cells in 6wells were transfected with 500 ng pSUPuro-
scr or pSUPuro FUS for the CTR knockdown or the FUS
knockdown, respectively. For the rescue condition, each 500
ng additional pcDNA6F-FUS, pcDNA6F-FUS PLD27YS
or pcDNA6F-FUS PLD27YS SV40NLS were transfected.
Twenty-four hoursx after transfection, the cells were split
into two wells of a six-well plate and selection for the
pSUPuro plasmids was started using 2 g/ml Puromycin
(CAS 58-58-2, Santa Cruz). Selection was maintained for
36 h. Cells were harvested 72 h after transfection as above
(one well for RNA isolation, one well for western blotting).
For the E1A minigene reporter assay, 250 ng pcDNA6F-
mEGFP, 500 ng pcDNA6F-FUS or 250 ng pcDNA6F-
FUS PLD27YS SV40NLS along with 200 ng pEGFP-C1-
E1A were transfected to HeLa cells in six-well plates at 80%
confluency using Lipofectamine 2000 (11668019, Thermo
Scientific). All plasmid mixes were filled up to 1 g of to-
tal DNA using empty pcDNA3.1(+). Cells were harvested
48 hours post transfection and RNA isolation and western
blotting was performed as described above.
RT-qPCR
RNA was isolated from cells using TRIZOL (TRI
Reagent™ Solution, AM9738, Thermo Fisher) supple-
mented with 1:100 -Mercaptoethanol (A1108, PanReac
Applichem) according to the manufacturer’s instructions.
RNA for the SCN4A reporter assay was DNase treated
using the TURBO DNA-free™ Kit (AM1907, Thermo
Fisher) prior to cDNA synthesis according to the man-
ufacturer’s instructions. RNA quantity was determined
using the NanoDrop™ One/OneC Microvolume UV–Vis
Spectrophotometer (Thermo Fisher). cDNA was generated
from 1 g RNA using the AffinityScript Multiple Temper-
ature cDNA Synthesis Kit (00436, Agilent Technologies)
according to the manufacturer’s instructions using random
hexamer primers (150 ng/l) (Sigma Aldrich). To confirm
successful DNase treatment, a control reaction omitting
the reverse transcription enzyme was prepared. The cDNA
was diluted to a RNA concentration of 8 ng/l. qPCR
was performed using the Takyon No ROX SYBR 2X Mas-
terMix blue dTTP (UF-NSMT-B0701, Eurogentec) with a
final MgCl2 concentration of 4 mM. For the E1A mini-
gene reporter assay, 2 g of RNA were reverse transcribed
using the high-capacity RNA-to-cDNA kit (4387406, Ap-
plied Biosystems) according to the manufacturer’s instruc-
tions. qPCR was performed using the MESA green no ROX
SYBR 2× Master mix plus (RT-SY2X-06+NRWOU, Euro-
gentec). All samples were measured in technical duplicates:
3 l of cDNA were amplified in a total volume of 15 l con-
taining each 600 nM forward and reverse primer using the
Rotor-Gene Q 2plex Platform (Quiagen) with the follow-
ing cycling parameters: 5 min 95◦C (initial denaturation), 20
s 60◦C, 5 s 95◦C (40 cycles). After cycling, a melting curve
was recorded from 65◦C to 95◦C rising by 1◦C each step.
Analysis was performed as described previously (45). Sta-
tistical significance of qPCR results was determined by un-
equal variances t-test using log-transformed splicing ratios.
RNA FISH combined with immunofluorescence
HeLa cells were grown to 80% confluency in six-well plates
and transfected with 1 g of the FUS expression con-
structs. The next day, 40 000 transfected cells were re-seeded
into eight-well slides (Merck, PEZGS0816) and incubated
overnight. FISH/IF was essentially performed as described
in (12). In brief, the cells were fixed with 4% PFA for 15 min,
permeabilized in 70% Ethanol at 4◦C for 48 h and blocked
with blocking buffer (1% BSA (A7030, Sigma Aldrich) in
PBS, supplemented with 2 mM Ribonucleoside Vanadyl
Complexes (R3380, Sigma Aldrich). Antibodies were di-
luted in blocking buffer and incubated at room temperature
for 1 hour (primary) and 2 h (secondary), respectively. Sub-
sequently, antibody complexes were cross-linked to their
targets using 4% PFA for 5 min. Following equilibration in
2× SSC (300 mM NaCl, 30 mM sodium citrate pH 7.0), and
incubation in pre-hybridization buffer (15% Formamide
(17899, Thermo Scientific), 10 mM sodium phosphate, 2
mM RVC in 2× SSC, pH 7.0) at 42◦C for 10 min, 6-FAM
azide labelled antisense probes were diluted to 0.5 ng/l
in hybridization buffer (15% Formamide, 10 mM sodium
phosphate, 10% dextran sulfate (S4030, Merck), 0.2% BSA,
0.5 g/l Escherichia coli tRNA, 0.5 g/l salmon sperm
DNA (15632011, Invitrogen), 2 mM RVC in 2× SSC, pH
7.0) and hybridized to their targets over night at 42◦C. The
next day, unbound probes were removed by washing two
times 30 minutes with pre-hybridization buffer and three
times 10 min in high stringency wash solution (20% For-
mamide, 2 mM RVC in 0.05× SSC, pH 7.0). Then, the cells
were washed three times with 2× SSC before mounting with
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Silver staining
Proteins in LDS-loading buffer were separated on
a NuPAGE 4–12% Bis–Tris Midi Gel (WG1403A,
Thermo Fisher) or on a Bolt™ 4–12% Bis–Tris Plus Gel
(NW04120BOX, Thermo Fisher). The gel was incubated
for 2 h at room temperature in fixing solution (50% MeOH,
12% HAc, 0.05% formalin). The gel was subsequently
washed 3 × 20 min at room temperature in 35% EtOH.
Thereafter, the gel was sensitized in 0.02% Na2S2O3 for 2
min, washed 3 × 5 min in ultrapure water and incubated
for 20 min at room temperature in silver staining solution
(0.2% AgNO3, 0.076% formalin). Then, the gel was washed
2 × 1 min in ultrapure water and developed in developing
solution (6% Na2CO3, 0.05% formalin, 0.0004% Na2S2O3).
Upon desired band intensities, the reaction was stopped
by replacing developing solution with stop solution (50%
MeOH, 12% HAc) and incubating for 5 min.
RESULTS
Determining the liquid–liquid phase separation dependent
FUS interactome
In order to determine which protein and RNA species inter-
act with FUS under LLPS conditions, we developed a novel
approach which allows for the purification of phase sepa-
rated FUS from cell lysates based on the purification of en-
hanced green fluorescent protein (eGFP)-tagged wild type
FUS (summarized in Figure 1A). To identify possible alter-
ations in the interactome of ALS-associated mutant FUS,
we additionally employed eGFP-FUS P525L, an aggres-
sive ALS-linked mutant where the C-terminal NLS is dis-
rupted, leading to cytosolic mislocalization of FUS (21). To
validate that both, eGFP-FUS and eGFP-FUS P525L, are
capable of undergoing LLPS and forming liquid-like com-
partments in cells, we performed fluorescence recovery after
photobleaching (FRAP) on HeLa FUS-KO cells transiently
transfected with either FUS WT-GFP or FUS P525L-GFP
and photobleached eGFP-FUS granules (nuclear for WT
or cytoplasmic for P525L), and a nearby area to assess fluo-
rescence recovery. We observed a fast recovery for both WT
and P525L granules, reaching a maximum recovery within
∼20 s (Supplementary Figure S1a). Given that the hallmark
of liquid-like structures is the dynamic reorganization and
rapid exchange of proteins (46), our rapid recovery time is
comparable to previous studies (4,47,48) and indicates that
spontaneously generated FUS granules display liquid-like
properties.
For our interactome studies, we transiently expressed
FLAG-eGFP, eGFP-FUS and eGFP-FUS P525L in
HEK293T cells (Figure 1B). It was previously shown that
under physiological salt concentrations GFP-FUS starts to
undergo LLPS in vitro, either through increasing concentra-
tions above physiological concentrations of FUS or through
the addition of a molecular crowding agent such as dextran
(49). Following the same rationale to reach sufficient eGFP-
FUS concentration for eGFP-FUS to undergo LLPS after
cell lysis in the lysate, the volume of the cell lysate was con-
centrated 2-fold to the approximate volume of the initial cell
pellet, thus restoring endogenous protein concentrations to
near physiological levels. This volume reduction resulted
in the formation of eGFP-FUS- and eGFP-FUS P525L-
containing droplets in the cell lysate, which can be visu-
alized by fluorescence microscopy (Supplementary Figure
S1b, c, and Supplementary video). Importantly, no droplets
were formed by FLAG-eGFP alone, confirming that FUS
specifically drives phase separation (Supplementary Figure
S1e). To further ensure that the concentration approach is
not an inherent source of global protein aggregation, we
co-expressed eGFP-FUS P525L with a soluble control pro-
tein (GB1-TwinStrep-RFP) and monitored droplet forma-
tion by fluorescence microscopy. While eGFP-FUS robustly
formed droplets after volume reduction at an approximate
concentration of 20 M, GB1-TwinStrep-RFP remained
dispersed and was not enriched in FUS-droplets even at 10-
fold higher concentrations (Supplementary Figure S2a, b).
The eGFP-FUS droplets were then stabilized using the
reversible crosslinker formaldehyde, which rendered them
stable enough to be analysed by flow cytometry (Supple-
mentary Figure S1e) and to be sorted by fluorescence ac-
tivated particle sorting (FAPS) (50) (Supplementary Fig-
ure S1d). To address which protein and RNA species
interact with FUS under non-LLPS conditions, a regu-
lar co-immunoprecipitation (co-IP) was performed using
nanobodies against eGFP. As phase separation of FUS
is highly dependent on FUS concentration (4,49) and the
wash volumes applied during the co-IP exceeded the vol-
ume applied to analyse the cell lysates in Supplementary
Figure S1e, LLPS of FUS during co-IP conditions is limited
or even completely prevented. A pulldown of FLAG-eGFP
served as control IP. Successful purification of the bait
from droplet purifications and co-IPs were verified by SDS-
PAGE followed by silver staining or western blotting, re-
spectively (Supplementary Figure S3). Proteins and RNAs
purified from co-IP and droplet purification experiments
were analysed by label-free quantitative mass spectrometry
or RNA deep sequencing, respectively. Interestingly, wild
type and P525L FUS protein and RNA interactomes (un-
der the same experimental conditions) were mostly identi-
cal (Supplementary Figure S4). This is most likely due to
the fact that FUS and FUS P525L are both nuclear and cy-
toplasmic due to the ectopic overexpression (21,51). There-
fore, wild type and P525L interactomes from the same ex-
perimental conditions were pooled, to increase statistical
power for the identification of the most robust FUS interac-
tors under LLPS and non-LLPS conditions. We identified
238 proteins interacting with FUS under LLPS conditions
and 360 under non-LLPS conditions. 102 proteins were
present in both datasets (independent of the biophysical
state), resulting in 136 proteins specific for the LLPS condi-
tion. The observation that several proteins and RNAs pref-
erentially interacted with FUS under LLPS conditions (Fig-
ure 1C and Supplementary Table S1) indicates that altered
biophysical conditions within phase separated droplets en-
able FUS to undergo previously unknown interactions. Of
note, while many proteins did not pass the statistical crite-
ria (see material and methods) to be assigned to both in-
teractomes, many proteins assigned to either the LLPS or
the non-LLPS interactome were detected under both LLPS
and non-LLPS conditions. Indeed, 70% of the LLPS inter-
actors were detected in the non-LLPS condition, while 81%
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Figure 1. Co-IP and purification of LLPS FUS followed by quantitative mass spectrometry and RNA deep sequencing. (A) Experimental workflow.
HEK293T cells expressing wild type or P525L eGFP-FUS fusion protein are lysed and subsequently subjected either to a co-IP experiment using anti-GFP
nanobodies coupled to magnetic beads (left path) or to eGFP-FUS droplet purification (right path). Droplets are generated through reducing the volume
of the lysate and stabilized using the reversible crosslinker formaldehyde. Thereafter, the droplets are purified by fluorescence-activated particle sorting and
additional wash steps. (B) Constructs used for co-IP and droplet purification experiments. eGFP fused to FUS including a GSG15 linker between the two
proteins. Wild type eGFP-FUS (top right) localizes mainly to the nucleus whereas ALS mutant P525L eGFP-FUS (bottom right) localizes predominantly
to the cytoplasm as shown by fluorescence microscopy of transiently transfected HeLa cells counterstained with DAPI. Scale bar = 30 m. (C) Summary
of quantitative mass spectrometry (top) and RNA deep sequencing (bottom) experiments. Shown are numbers for protein and RNA species, which were
significantly enriched in co-immunopurification and droplet purification experiments comprising the respective overlap between the two datasets.
periment. This indicates different binding, but not necessar-
ily mutually exclusive binding to FUS, depending on its bio-
physical state. We further analysed proteins co-purified with
FUS under LLPS and non-LLPS conditions, comparing
them to previously reported FUS interactors (12,31–36). In-
terestingly, only 23.8% of the LLPS-dependent FUS inter-
actors have been previously reported, whereas 47.2% of the
co-immunoprecipitated FUS interactors have already been
reported by these previous studies (12,31–36). This is in line
with the idea that phase separation changes the biomolec-
ular interactions of FUS. As aforementioned studies used
non-LLPS conditions (co-immunoprecipitations) to purify
FUS and its interaction partners, it is not surprising that
there are clearly more previously unknown FUS interactors
present in the LLPS-dependent FUS interactome.
While compared to the number of significantly enriched
protein interactors, higher numbers of RNAs could be iden-
tified in FUS droplets (1761) or co-IPed together with FUS
(2,261), with 411 RNAs significantly enriched in both sam-
ples (Figure 1C and Supplementary Table S2), the overall
picture of the RNA interactome is similar to the protein
interactome. More interactors were identified in the co-IP
compared to the droplet purification experiment, and the
relative overlap between the two samples is similar for both
protein and RNA interactomes.
FUS has a different protein interactome depending on its bio-
physical state
In order to identify protein families enriched in LLPS
and non-LLPS conditions, we performed a protein net-
work analysis using STRING (42) on the 136 proteins
that were exclusively co-purified with FUS under LLPS
conditions and compared them to all the proteins (n =
360) that were co-immunoprecipitated together with FUS
(non-LLPS conditions). Interestingly, STRING classified
LLPS-specific FUS interactors into three main functional
groups (Figure 2A), namely proteins with functions in mi-
tochondria (red), proteins involved in chromatin remod-
elling and DNA damage response (blue) and proteins in-
volved in RNA splicing (green). Although enriched in the
LLPS-specific FUS interactome, proteins involved in RNA
splicing were much more prominent among proteins co-
immunoprecipitated together with FUS (Figure 2B, green).
In line with this finding, performing gene ontology (GO)
term enrichment analyses on the same groups of proteins
using the WEB-based GEne SeT AnaLysis Toolkit (We-
bGestalt) (43) revealed that factors involved in RNA splic-
ing and mRNA processing were enriched much more sig-
nificantly in the non-LLPS FUS interactome compared to
the LLPS-specific FUS interactome (Supplementary Figure
S5a).
To validate the proteins detected by mass spectrometry,
we performed western blot analysis of proteins involved in
RNA splicing, chromatin remodelling and DNA damage
repair and factors with functions in mitochondria (Figure
2C). While some proteins showed the same binding to FUS
regardless of LLPS, such as hnRNP H and hnRNP A1, oth-
ers showed a clear preference for either LLPS or non-LLPS
conditions. Consistent with the mass spec data (Supplemen-
tary Table S1), proteins involved in mRNA splicing were
co-purified with FUS independent of its biophysical state.
Nonetheless, they seemed to interact with FUS preferen-
tially under non-LLPS conditions. Furthermore, proteins
involved in chromatin remodelling and DNA damage re-
sponse as well as mitochondrial proteins were almost exclu-
sively detectable together with phase separated FUS. Inter-
estingly, nuclear FUS granules have already been reported
to associate with RNA polymerase II (RNA Pol II), and
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Figure 2. Preferential protein interaction partners depending on FUS biophysical state and dysregulated mitochondrial protein homeostasis at an early
stage in FUS-ALS. (A) STRING analysis of LLPS-specific FUS interactors (n = 136). Highlighted are proteins with biological functions in RNA splicing
(green, GO:0008380), chromosome organization and cellular response to DNA damage stimulus (blue, GO:0051276 and GO:0006974) and proteins mi-
tochondrial functions (red, GO:0006839, GO:0007005 and GO:0006811). A high-resolution image is available in Supplementary Materials. (B) STRING
analysis of non-LLPS interactors of FUS (n = 360). Highlighted are proteins with biological functions in RNA splicing (green, GO:0008380), translation
(cyan, GO:0006412) and ribosome biogenesis (magenta, GO:0042254). A high-resolution image is available in Supplementary Materials. (C) Western blot
analysis of proteins co-immunoprecipitated (non-LLPS) with control (FLAG-eGFP, lane 4) or FUS (lane 5–6) and purified together with FUS droplets
(LLPS, lanes 7–8). (D) Scheme of the ‘FUSDelta14’ knockin mouse ALS model. A reported ALS mutation (FUS p.G466VfsX14) destroys the 3′ splice
site of exon 14 leading to exon skipping resulting in a novel C-terminus deleting the endogenous FUS NLS. To generate the identical frameshift peptide to
that of the human patient, human exon 15 coding sequence was also knocked-in. (E) Western blot analysis of spinal cord lysates from 9 month old FUS+/+
(lanes 1–4) and FUS14/+ (lanes 5–8) mice. While FUS+/+ mice only express full-length Fus, FUS14/+ mice express full-length and the shorter 14 Fus.
-actin served as loading control. (F) As in E, but showing changes in mitochondrial protein levels. Protein levels were normalized to total protein levels
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also the transcriptional activator domain of FUS-CHOP
and FUS-ERG fusion proteins observed in cancer, is suf-
ficient to target the SWI/SNF chromatin remodelling com-
plex (5,52–56). Moreover, chromatin remodelling is an im-
portant aspect of DNA damage response and FUS gran-
ules have already been reported at sites of DNA damage
(4). In line with this data, proteins involved in the DNA
damage response were specifically enriched with phase sep-
arated FUS. Strikingly, we also detected the members of
mammalian cleavage factor I (CFIm) in our LLPS FUS in-
teractome. Besides its function in mRNA 3′-end process-
ing, CFIm has also been linked to chromatin remodelling
(57) and is a component of paraspeckles which require FUS
as structural component (58–61). The most unexpected and
at the same time prominent LLPS-dependent FUS interac-
tors, however, were proteins with function in mitochondria.
To ensure that the identified LLPS-dependent interac-
tors are not artefacts from post-cell lysis protein rear-
rangements as well as formaldehyde crosslinking, we de-
cided to further validate the interactions of FUS with
TOM-20, VDAC1, SMARCA4 and CPSF6, which were
only present in purified FUS droplets, as well as hnRNPH
and hnRNPA2/B1, which were present both in the FUS
co-IP and the FUS droplets. In our analysis we also in-
cluded hnRNP K, which was significantly enriched in FUS
droplets compared to the FUS co-IP (Supplementary Ta-
ble S1) in order to analyse an hnRNP that displays se-
lectivity to phase separated FUS. To preserve the phase
separated state as well as to prevent post-lysis rearrange-
ments, we performed in situ DSP/DTME crosslinking (62)
of FLAG-tagged FUS P525L transfected 293T cells fol-
lowed by immunoprecipitation from total extracts. Indeed,
while hnRNP H and hnRNP A2/B1 co-precipitated in
both, crosslinked or uncrosslinked conditions, hnRNP K as
well as TOM-20 were only co-immunoprecipitated at a de-
tectable level under crosslinked conditions, in line with their
preference for phase separated FUS (Supplementary Fig-
ure S5a). CPSF6 and SMARCA4 however were insoluble
in the IP buffer post-crosslinking (Supplementary Figure
S5b), and VDAC1 which only showed a slight enrichment
in the crosslinked IP compared to the uncrosslinked sample
(Supplementary Figure S5a) showed a reduction in solubil-
ity post crosslinking (Supplementary Figure S5b). Hence,
we performed proximity ligation assays for SMARCA4,
CPSF6, VDAC1 as well as TOM-20 on HeLa cells trans-
fected with either FLAG-FUS or FLAG-FUS P525L and
confirmed their interaction with FUS in intact cells (Sup-
plementary Figure S5c-e).
Consistent with previous reports showing that cytoplas-
mic FUS interacts with mitochondrial proteins and lo-
calizes into mitochondria (63–65), mitochondrial proteins
formed the top GO term in the LLPS-specific FUS inter-
actome (Supplementary Figure S6a). Intriguingly, it has
previously been reported that dysregulation in mitochon-
drial gene expression occurs at the initial disease stage in
‘FUSDelta14’ knock-in mice, which heterozygously express
FUS carrying a C-terminal frameshift mutation causing
deletion of the NLS (24). To assess if mitochondrial pro-
tein levels are affected at an early, pre-symptomatic stage
in the ‘FUSDelta14’ mouse model (Figure 2D and E),
we quantified proteins isolated from spinal cord sections
of pre-symptomatic mice by western blotting (Figure 2F
and G). Normalization was performed using total pro-
tein staining (Supplementary Figure S6b) instead of relying
on one single housekeeping gene. While proteins involved
in RNA processing, DNA damage repair and chromatin
remodelling appeared unchanged (Supplementary Figure
S6c), several mitochondrial proteins were dysregulated in
the ‘FUSDelta14’ knock-in mice. Of note, this was not due
a general change of mitochondrial homeostasis, as other
mitochondrial proteins remained unaffected (Supplemen-
tary Figure S6d). However, the exact mechanism for the ob-
served dysregulation of a subset of mitochondrial proteins
in the ‘FUSDelta14’ model and whether it is directly linked
to increased interaction with LLPS FUS remains to be elu-
cidated.
FUS has a different RNA interactome depending on its bio-
physical state
While mRNAs were the most abundant RNAs associated
with either FUS droplets (LLPS conditions) or non-phase
separated FUS (co-IP) (Figure 3A-C), the most promi-
nently enriched RNA species co-purified with FUS under
both conditions were U snRNAs (Figure 3D and E). U snR-
NAs are the RNA components of small nuclear ribonuclear
particles (snRNPs) and are responsible for recognition and
removal of introns from pre-mRNAs during splicing (66).
Newly transcribed snRNAs are exported to the cytoplasm
where a heptameric ring of Sm proteins is assembled onto
them to generate a core snRNP. This core snRNP is then
re-imported into the nucleus where snRNP-specific proteins
(such as U1A in case of the U1 snRNP) assemble with the
core snRNP to form the fully assembled, mature snRNP
(67). Interestingly, in cells expressing FUS with NLS muta-
tions the U1 core snRNP was found to mislocalize to the
cytoplasm (68–70).
An enrichment for snRNAs was expected with non-phase
separated FUS, as proteins involved in pre-mRNA splic-
ing are also strongly enriched under non-LLPS conditions.
However, the strong enrichment of snRNAs together with
phase separated FUS was rather surprising, as snRNP pro-
tein components are not significantly enriched together with
LLPS FUS. Interestingly, we and others have previously re-
ported that cytoplasmic FUS granules sequester U snR-
NAs or SmB-associated U snRNAs, but not fully assem-
bled snRNPs (12,68–70). Indeed, we could recapitulate that
ALS-linked FUS P525L cytoplasmic foci bind U1 and U11
snRNAs in the cytoplasm, whereas the U1 snRNP spe-
cific protein U1A remains nuclear (Figure 3G). Together
with our FRAP experiments (Supplementary Figure S1a)
that indicate that cytoplasmic FUS P525L foci behave like
phase separated bodies and our interactome data, this sug-
gests that phase separated FUS in the cytoplasm preferen-
tially binds partially assembled core snRNPs or unassem-
bled snRNAs. Indeed, we and others have already shown
that FUS contacts both the major (U2-type) and minor
(U12-type) spliceosome to regulate splicing of specific in-
trons (12,15,35). Finally, the biggest difference between the
two purification experiments was the strong enrichment of
mitochondrial ribosomal RNAs (MtrRNAs) (Figure 2F),
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Figure 3. RNA interactome of LLPS and non-LLPS FUS. (A) Relative abundance of different RNA species co-purified with LLPS FUS (FUS droplets).
(B) Relative abundance of different RNA species co-purified with non-LLPS FUS (co-IP). (C) Relative abundance of different RNA species in the input
sample. (D) fold change of relative RNA abundance of different RNA species comparing RNAs found under LLPS conditions relative to the input. (E)
Same as in D, but comparing RNA found in non-LLPS conditions compared to the input. (F) Same as in D, but comparing RNA abundance between
LLPS and non-LLPS conditions. (G) HeLa cells transiently transfected with either FLAG-FUS (left) or FLAG-FUS P525L (right) and stained for FLAG
(red channel) and different components of the U1 snRNP (green channel), either by RNA-FISH (U1 and U11, first and second row) or immunostaining
(U1A, third row). Cells were counterstained using DAPI. Scale bar = 15 m.
but clearly enriched in the LLPS condition. Importantly,
this is consistent with the proteomic data, where we detected
high levels of mitochondrial proteins purified together with
FUS droplets, but not in the co-IP condition.
LLPS is required for the association of FUS with chromatin
and its function in autoregulation
In order to assess the importance of FUS LLPS for FUS
function, we created an N-terminally FLAG-tagged FUS
construct and substituted 27 tyrosines in the N-terminal
prion-like domain (PLD) with serines (PLD27YS FUS).
The aromatic ring structures of the tyrosines in the FUS
PLD were previously shown to drive LLPS through inter-
and intramolecular cation- interactions with positively
charged amino acid side chains (49,71). Mutating these ty-
rosines to serines abolishes phase separation in vitro and
in vivo (5,49). Strikingly, PLD27YS FUS showed slightly
increased cytoplasmic localization compared to wild type
FUS (Figure 4A, first two rows). This suggests that be-
sides the C-terminal NLS of FUS, also the N-terminus
contributes to nuclear localization of FUS at steady state,
possibly through phase-separation-dependent nuclear in-
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Figure 4. Phase separation is required for FUS binding to chromatin and function in FUS autoregulation. (A) Immunostaining of HeLa cells transiently
expressing wild type FLAG-FUS, or LLPS-deficient FLAG-FUS PLD27YS and FLAG-FUS PLD27YS SV40NLS, respectively. Scale bar = 30 m. (B)
Western blot of cytoplasmic/nucleoplasmic versus chromatin fractionation experiment of HEK293T cells transiently expressing the constructs used in
A. The blots were incubated with antibodies against FLAG. GAPDH, RNA Pol II and Histone H3 serve as controls for the respective fractions. While
wild type FLAG-FUS is strongly bound to chromatin, phase separation deficient FUS is almost absent in the chromatin fraction. (C) Quantification of
western blots in B. Shown is the ratio of chromatin bound to cytoplasmic/nucleoplasmic FUS relative to the wild type FLAG-FUS construct. Average
values and standard deviation of three biological replicates are shown. (D) Western blot of HeLa cells which were either mock, FLAG-FUS, FLAG-FUS
PLD27YS or FLAG-FUS PLD27YS SV40NLS transfected. Total cell lysates were subjected to SDS-PAGE and western blotting with antibodies against
FLAG. Tyrosine tubulin served as loading control. (E) Endogenous FUS mRNA levels as determined by RT-qPCR relative to mock transfected cells.
Average and standard deviations of three biological replicates are shown. Single asterisk indicates a P-values of <0.05. (F) Western blot analysis of FUS
levels under control knockdown (CTR KD, lane 1), FUS KD (lane 2) and FUS rescue (lanes 3–5) conditions using wild type and LLPS-deficient FUS
constructs. Proteins from HeLa extracts were separated by SDS-PAGE and blots were incubated with anti-FLAG (upper row) and anti-FUS (middle row).
Tyrosine tubulin (lower row) serves as loading control. (G) Ratio of spliced to total RNA expressed from the SCN4A minigene (The minigene is driven
by a CMV promoter and expresses exon 2 and 3 and the intervening U12-type intron) under CTR KD, FUS KD and FUS KD followed by a rescue with
different RNAi-resistant expression constructs. Average values and standard deviations of three biological replicates are shown. Double asterisk indicates
a P-values of <0.01. (H) Relative endogenous FUS mRNA levels from samples analysed in G. (I) Western blot of HeLa cells which were transfected
with either FLAG-EGFP, FLAG-FUS, or FLAG-FUS PLD27YS SV40NLS. Total cell lysates were subjected to SDS-PAGE and western blotting with
antibodies against FLAG. GAPDH served as loading control. (J) Ratios of 9S, 12S and 13S isoforms expressed from the E1A minigene under FLAG-
EGFP, LLPS-proficient FLAG-FUS or LLPS-deficient FLAG-FUS PLD27YS SV40NLS overexpression. Average values and standard deviations of three
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the N-terminus of FUS is required for binding of FUS to
chromatin (72), where FUS localizes to granules and reg-
ulates gene expression in a transcription-dependent man-
ner. Moreover, inhibition of transcription leads to cyto-
plasmic re-localization of FUS, suggesting that active tran-
scription tethers FUS to newly synthesized RNA bound
to chromatin (4,53,54). This is consistent with the recent
finding that FUS leaves the nucleus through passive dif-
fusion (73). If LLPS is indeed required for FUS binding
to chromatin, one would expect more FUS diffusing from
the nucleus to the cytoplasm if phase separation is in-
hibited. To be able to study the importance of LLPS for
FUS function in the nucleus and to exclude that a loss of
function is not due to FUS mislocalization, we generated
a phase separation-deficient FUS construct with an addi-
tional strong SV40 NLS to ensure nuclear localization (Fig-
ure 4A, last row). To investigate the importance of LLPS
for the ability of FUS to bind to chromatin, we transiently
expressed wild type and LLPS-deficient FUS in HEK293T
cells, followed by a cytoplasmic/nucleoplasmic versus chro-
matin biochemical fractionation. Indeed, LLPS-deficient
FUS hardly interacted with chromatin compared to the wild
type FUS (Figure 4B and C), indicating that phase separa-
tion is required for FUS function in co-transcriptional gene
expression.
To test if LLPS-deficient FUS is still functional, we made
use of three previously established assays for FUS func-
tion. First, we tested if PLD27YS FUS is still capable of
autoregulating endogenous FUS mRNA levels when tran-
siently transfected into HeLa cells (74). While wild type
FUS autoregulated endogenous FUS mRNA levels, LLPS-
deficient FUS had no effect on endogenous FUS mRNA
levels (Figure 4D and E). Importantly, this was not due cy-
toplasmic mislocalization of PLD27YS FUS as the addi-
tion of the SV40 NLS did not rescue FUS function in au-
toregulation (Figure 4D and E). Next, we used the minor
(also referred to as U12-type) intron containing SCN4A
minigene, which requires FUS for efficient splicing (12).
If cells are depleted of FUS, splicing of the SCN4A mini-
gene becomes less efficient and this effect can be rescued
by transient expression of RNAi-resistant FUS. Surpris-
ingly, LLPS-deficient FUS was still able to promote efficient
splicing (Figure 4F and G), even though it was unable to
autoregulate. While PLD27YS FUS was only partially ac-
tive, PLD27YS FUS harbouring the additional SV40 NLS
fully rescued splicing of the SCN4A minigene. This differ-
ence presumably occurs due to the partial cytoplasmic mis-
localization of PLD27YS FUS, which is rescued upon the
addition of an additional NLS. Importantly, these differ-
ences did not emerge from differences in knockdown effi-
ciencies of endogenous FUS, which are identical between
the experimental conditions (Figure 4H). Finally, we used
the well-established E1A minigene assay to assess the im-
pact of LLPS in FUS’s function in major (U2-type) 5′ splice
site selection. Overexpression of FUS was previously re-
ported to increase the usage of a distal 5′ splice site on the
E1A pre-mRNA resulting in an increased expression of the
9S isoform at the expense of proximal splice site selection,
leading to reduced formation of the 12S and 13S isoforms
(72,75–77). Indeed, we observed the same effect for wildtype
FUS as well as LLPS-deficient FUS harbouring the addi-
tional SV40 NLS (Figure 4I and J), suggesting that LLPS is
not required for FUS’s function in alternative 5′ splice site
selection in the context of major intron splicing. The capa-
bility of LLPS-deficient FUS to promote splicing is in line
with our observation that non-phase separated FUS pref-
erentially interacts with proteins involved in RNA splicing,
indicating that phase separation is not necessary for FUS
function in splicing.
Cytoplasmic FUS LLPS is not required for FUS toxicity, but
for the formation of stress granules
It was previously reported that increased levels of FUS in
vivo, either by overexpression or disruption of regulatory
circuits, are associated with progressive motor neuron de-
generation and ALS (51,78–80) and suggested that phase
separation of FUS in the cytoplasm, followed by aggre-
gation, drives disease (25,26). To assess whether LLPS of
FUS is a prerequisite for the observed FUS toxicity, we per-
formed MTT assays with HeLa cells transiently expressing
FLAG peptide, FLAG-tagged wild type FUS, FUS P525L
and LLPS-deficient FUS P525L (Figure 5A and B). As ex-
pected, overexpression of either wildtype or P525L FUS re-
sulted in decreased cell viability in line with previous stud-
ies reporting that overexpression of FUS has deleterious
effects in different models (51,78–80). Interestingly, LLPS-
deficient FUS-P525L reduces cell viability to the same ex-
tent as LLPS-proficient FUS-P525L. To corroborate these
results, we also assessed release of cytochrome c from mi-
tochondria to the cytoplasm, a key step during the mito-
chondrial apoptotic pathway (81) (Supplementary Figure
S7a, b). To assess the impact of LLPS on this pathway we
transfected 293T cells either with empty pcDNA3.1(+) as
control, FUS P525L and LLPS-deficient FUS P525L. Over-
expression of either wild type or mutant FUS caused an
increase in cytochrome c release, and in line with the re-
sults from the cell viability assay, LLPS-deficient FUS did
not result in a reduction of released cytochrome c (Supple-
mentary Figure S7a-b). To exclude potential toxic effects of
the transfection reagent used for this experiment, untreated
cells were compared to mock transfected cells, excluding a
toxic effect of the transfection reagent (Supplementary Fig-
ure S6c and d). Overall, these data indicate that LLPS is not
a prerequisite for FUS to exert deleterious effects on cells
upon overexpression.
As FUS aggregates were suggested to exert a toxic
function, we compared the solubility of LLPS-competent
and LLPS-deficient FUS. To this end, half of the cells
transfected for the mitochondrial/cytoplasmic fractiona-
tion were subjected to a RIPA soluble/insoluble biochem-
ical fractionation experiment. As previously reported (82),
ALS mutant cytoplasmic FUS exhibited reduced solubil-
ity compared to wild type FUS (Figure 5C and D). Inter-
estingly, LLPS-deficient cytoplasmic FUS was more solu-
ble than both wild type and cytoplasmic LLPS-competent
FUS. Indeed, it was already shown, using purified FUS pro-
tein in vitro, that phase separation precedes the formation
of insoluble aggregates (4). Our data strongly suggests that
also in more complex environments, such as cell systems
and in vivo, phase separation is involved in the formation of
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Figure 5. LLPS is not required for cytoplasmic FUS toxicity. (A) Effect of FLAG-FUS, FLAG-FUS P525L and FLAG-FUS PLD27YS P525L on cell
viability compared to FLAG transfected control using the MTT assay. MTT data are expressed as the average viability in relation to FLAG control and
were analysed using one-way ANOVA, followed by Bonferroni post-hoc test for group-wise comparisons. Two biological replicates with three technical
replicates were performed (n = 6). Triple asterisks indicate a P-value <0.001. (B) Quantification of transfection efficiency of cells analysed in A. Transfected
cells were immunostained against FLAG and positivity was assessed by FACS. (C) Western blot of soluble/insoluble fractionation of the cells transfected
in A. Membranes were incubated with anti-FLAG antibodies. Tyrosine tubulin served as a loading control. (D) Quantification of FUS levels in (C). Shown
is the ratio of soluble to insoluble FUS relative to wild type FLAG-FUS. Average values and standard deviation from five biological replicates are shown.
(E) Immunostaining of arsenite-treated HeLa cells transiently transfected with LLPS-proficient (WT-PLD) or LLPS-deficient (27YS-PLD) FLAG-FUS
R495X constructs lacking the C-terminal NLS. Cells were stained for Flag (green), the SG marker TIA-1 (red) and DAPI (blue). Scale bar = 20 m. (F)
Quantification of percentage of cells with TIA-1+ SGs (scored in at least 50 cells/experiment from three independent experiments), bar graph shows means
and standard deviations. Average values and standard deviations from three biological replicates are shown. Asterisk indicates a P-value < 0.05 (Student’s
t-test, two sided).
anism by which FUS aggregates observed in post-mortem
tissue of ALS-FUS patients are formed.
It has been postulated that recruitment of FUS to stress
granules (SGs) may be a first step in the formation of in-
soluble FUS aggregates (20,21). Indeed, SGs are phase sep-
arated cytoplasmic compartments (83), and various stud-
ies have reported FUS localization to SGs, in particu-
lar when FUS is mislocalized to the cytoplasm due to a
NLS mutation (21,84–86). In order to investigate the ef-
fect of LLPS on SG recruitment of FUS, we transiently
transfected HeLa cells with NLS-deficient FUS R495X or
FUS R495X PLD27YS (LLPS-deficient), induced SGs us-
ing sodium arsenite and then monitored SG recruitment
of FUS using fluorescence microscopy. As expected, NLS-
deficient cytosolically mislocalized FUS was efficiently re-
cruited to TIA-1-positive SGs (Figure 5E), as previously
reported (21,44,86). In contrast, LLPS-deficient cytosolic
FUS remained mainly diffuse and very few TIA-1-positive
SGs were seen in FUS-PLD27YS-expressing cells upon ex-
posure to sodium arsenite stress (Figure 5E, see F for quan-
tification), suggesting that SG formation is suppressed by
LLPS-deficient FUS. This is a surprising finding, given that
SG formation does not require FUS (87). To exclude the
possibility that LLPS-deficient FUS only prevents TIA-1
from being recruited to SGs, but not SG formation per
se, we performed the same experiment with immunostain-
ing for other well-defined SG markers in HEK293T cells
(TIAR and G3BP1). As observed for TIA-1, these other
SG marker proteins also showed reduced localization to
granular structures after arsenite stress in cells expressing
LLPS-deficient cytosolic FUS (Supplementary Figure S8a
and b), suggesting that SG formation may indeed be re-
duced by the presence of LLPS-deficient FUS. To further
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oxidative stress, we also applied osmotic stress to HEK293T
cells transiently expressing the aforementioned FUS con-
structs using D-sorbitol. Consistent with the oxidative stress
condition, LLPS-deficient FUS also reduced the formation
of SGs under osmotic stress (Supplementary Figure S8c).
Two possible explanations for this behaviour are: Either
LLPS-deficient FUS protects cells from oxidative and os-
motic stress, or LLPS-deficient FUS prevents SG forma-
tion through sequestration of factors required for this pro-
cess. Although the first possibility cannot be excluded at
this point, it seems rather unlikely, especially since LLPS-
deficient FUS affects cell viability to the same extent as
LLPS-competent FUS in our experiments. Interestingly, we
(Figure 2 and Supplementary Table S1) and others (33–
35,86) identified interactions between FUS and different
SG marker proteins. Hence, we suggest that LLPS-deficient
FUS might sequester factors required for SG formation and
thus may prevent their incorporation into SGs during stress,
thereby affecting SG assembly.
In summary, we provide evidence that LLPS and aggrega-
tion of FUS are not required to exert cellular toxicity upon
FUS overexpression. Nonetheless, LLPS of FUS seems to
be important for the formation of SGs and recruitment of
FUS to these membrane-less organelles, a process that may
proceed to the formation of insoluble FUS aggregates.
DISCUSSION
In this study, we describe a novel method that allows for the
purification of liquid–liquid phase separated proteins com-
bining chemical crosslinking with fluorescence-activated
particle sorting. Like every experimental approach, also this
method has limitations which should be considered. Simi-
lar to co-immunoprecipitation experiments where post lysis
rearrangements have been described (88), re-arrangements
or interactions that are not occurring under physiological
conditions might also arise following this approach when
purifying liquid–liquid phase separated proteins. Hence,
performing orthogonal assays such as in situ DSP/DTME
crosslink followed by immunoprecipitation, proximity lig-
ation assays and functional experimental readouts are es-
sential in order to validate newly identified interactions by
our LLPS droplet purification method. Moreover, includ-
ing a fluorescent control can help to detect global aggrega-
tion which should be avoided as it would trap proteins and
RNAs in a non-specific manner. Finally, normalization of
the co-purified proteins and RNAs to their respective in-
put abundance is crucial for the interpretation of the LLPS
dependent interactome data. As for CLIP-Seq experiments
where read counts depend on the expression level of a tran-
script making normalization to input RNA levels a critical
step in the CLIP-Seq workflow (89), highly abundant pro-
tein and RNA species are expected to be crosslinked to the
bait protein following the LLPS droplet purification work-
flow by chance. Interactors that bind preferably or exclu-
sively under phase separating conditions are expected to be
significantly enriched in the LLPS interactome compared to
the input.
This approach allowed us to identify new and validate
previously reported FUS interactors. In order to validate
previously unknown interactions, we performed orthogonal
assays to confirm that these interactions occur under phys-
iological conditions. We show that LLPS changes the FUS
interactome, presumably due to altered local concentrations
of FUS and its interactors, favouring these interactions in
phase separated compartments. Nevertheless, many FUS
interactors are detected under both conditions but show a
clear preference for either dispersed/soluble or phase sep-
arated FUS. Importantly, several proteins enriched with
phase separated FUS, such as DDX3X, DHX9, FMR1,
TIA-1 and SMN1 (compare Supplementary Table S1), have
already been observed by others to co-localize with FUS
into cytoplasmic granules (33,34,86,90). Moreover, proteins
found in nuclear granules, specifically paraspeckles (61)
and transcription-dependent granules containing FUS and
RNA Pol II (53), are highly enriched under LLPS condi-
tions compared to non-LLPS conditions (compare data in
Supplementary Table S1).
We identified factors involved in chromatin remodelling
and DNA damage repair to be the most prominent nu-
clear protein families binding with high preference to LLPS
FUS. Interestingly, it has been observed that LLPS occurs
at site of DNA damage (91,92). Strikingly, FUS was re-
cently shown to be required for the correct recruitment
of DNA damage repair factors to sites of DNA damage.
Importantly, this process is dependent on FUS-induced
LLPS, which is required for the recruitment of SFPQ,
as LLPS-deficient FUS failed to recruit SFPQ to sites of
DNA damage (93). Of note, SFPQ is one of most enriched
proteins identified in our LLPS-dependent FUS interac-
tome (Supplementary Table S1). Besides LLPS emerging
as an important factor in DNA damage response, numer-
ous recent studies reported that transcription factors re-
cruit the mediator coactivator complex through phase sep-
aration using their activation domains leading to recruit-
ment of RNA Pol II binding RNA Pol II C-terminal do-
main (CTD) (48,94–97). Noteworthy, FUS was previously
reported to interact with the CTD of RNA Pol II (13) and
was identified in transcription-dependent granules together
with RNA Pol II (53). Moreover, the N-terminal domain of
FUS, which was identified as the transcriptional activator
in FUS-CHOP and FUS-ERG fusion proteins in liposar-
coma and myeloid sarcoma respectively (54,55), was re-
cently shown to be sufficient to contact the SWI/SNF chro-
matin remodelling complex (52). Strikingly, protein compo-
nents of the mediator complex as well as protein subunits of
RNAP II detected by mass spectrometry are clearly more
abundant under LLPS conditions. Indeed, many of these
proteins were exclusively detected in the LLPS condition
while they were completely absent under non-LLPS condi-
tions (Supplementary Figure S9). In addition, components
of the mammalian pre-mRNA 3′ end processing factor
CFIm (composed of NUDT21 (also CPSF5), CPSF6 and
CPSF7) which were linked to chromatin remodelling (57)
and paraspeckles (58), are more strongly enriched together
with LLPS FUS compared to non-LLPS FUS, while in con-
trast, the other members of the 3′-end processing machin-
ery have slightly higher enrichment under non-LLPS con-
ditions (Supplementary Figure S10). In line with the idea
that phase separation of FUS plays an important role in
its chromatin-associated function(s), we show that FUS re-
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LLPS-deficient FUS mostly dissociates from chromatin and
partially re-localizes to the cytoplasm. Most likely, LLPS
FUS binds to chromatin in a transcription-dependent man-
ner, since previous studies reported re-localization of FUS
to the cytoplasm upon transcription inhibition (4,54), and
FUS was found in transcription-dependent granules to-
gether with RNA Pol II (53). Our data further suggests
that LLPS is the driving force for FUS binding to chro-
matin. The cytoplasmic re-localization of LLPS-deficient
FUS, as a consequence of losing its nuclear tether, is con-
sistent with recent data showing that the prion-like domain
of FUS is required for chromatin association (72), and that
FUS predominantly exits the nucleus through passive dif-
fusion (73). In addition, we show that LLPS-deficient FUS
can no longer exert its autoregulatory function, suggesting
that during transcription FUS is recruited through LLPS to
the FUS gene to regulate its own expression.
In contrast, non-LLPS conditions facilitate the interac-
tion between FUS and splicing factors. Moreover, LLPS is
not required to promote splicing of the minor intron con-
taining SCN4A reporter gene or for alternative 5′ splice site
selection in the E1A reporter gene. Of note, it has recently
been shown that TDP-43, another protein of the hnRNP
family that undergoes LLPS, does not to require phase sep-
aration to perform its function in pre-mRNA splicing (98).
This is in line with studies which performed in vitro splic-
ing assays in dependence on FUS or TDP-43, respectively
(14,99). Both studies used HeLa nuclear extracts where nu-
clear components are highly diluted (compared to the in
vivo context) and thus phase separation of either FUS or
TDP-43 very unlikely. Nonetheless, both proteins function
in splicing in the in vitro context. Altogether, these findings
strongly indicate that LLPS is not required for the function
of neither FUS nor TDP-43 in pre-mRNA splicing.
Besides providing evidence for the importance of LLPS
for FUS nuclear function in autoregulation, our data sug-
gests that LLPS and aggregation of FUS are not a prerequi-
site for reduced cell viability or increased apoptosis, at least
upon overexpression in in vitro experiments. Of note, re-
cent ALS-FUS mouse models, including the FUSDelta14
mouse that express cytoplasmic FUS from the endogenous
mouse locus or at endogenous levels, consistently showed
motor neuron degeneration in the absence of FUS aggre-
gation. Indeed, all of these studies failed to detect cyto-
plasmic FUS inclusion bodies which are observed in hu-
man tissue (22–24). Although toxicity of cytoplasmic FUS
aggregates cannot be excluded at this point, these find-
ings strongly indicate that increased cytoplasmic concen-
trations of FUS are sufficient for having deleterious effects,
leading to motor neuron death. Moreover, our data sug-
gests that FUS LLPS is not necessary for the toxic effects
of cytoplasmic FUS. It is therefore tempting to speculate
that under physiological conditions the formation of in-
soluble cytoplasmic FUS inclusions could be a mechanism
how cells reduce the amounts of cytoplasmic FUS, namely
through locally concentrating FUS, leading to FUS LLPS
and subsequent recruitment to SGs, followed by precipi-
tation through a liquid-to-solid state transition. Thereby,
FUS-LLPS might be a cellular mechanism to prevent (or
reduce) deleterious effects, reducing the amount of soluble
(toxic) FUS in the cytoplasm. Of note, this is not a new
concept in the field of neurodegeneration: similarly, amy-
loid plaques in Alzheimer’s disease have been proposed to
buffer toxic soluble amyloid-beta species (100). While it re-
mains to be established if LLPS and aggregation are dis-
pensable for cytoplasmic FUS toxicity in vivo, our data pro-
vides additional evidence that LLPS may indeed be the pre-
cursor of insoluble FUS aggregates, as LLPS-deficient FUS
is clearly more soluble than LLPS-competent FUS when
overexpressed in HEK293T cells. This indicates that, sim-
ilar to in vitro studies (4), also in cells LLPS is a prerequi-
site for liquid-to-solid state transition of FUS leading to the
formation of insoluble FUS aggregates. Additionally, while
LLPS-competent FUS robustly localizes to stress granules,
LLPS-deficient FUS does not localize to oxidative or os-
motic stress-induced stress granules and appears to even
suppress stress granule formation. This may be due to aber-
rant interactions of LLPS-deficient FUS with key SG pro-
teins, thereby interfering with SG nucleation. Alternatively,
LLPS-deficient FUS may destabilize certain interactions
within SGs and thus cause enhanced SG dissolution. In any
case, our data suggest that the formation of SGs is not nec-
essary for toxicity of cytoplasmic FUS, nor does SG forma-
tion protect against detrimental effects seen upon transient
FUS overexpression.
To conclude, we find that LLPS alters and expands the
interactome and functions of FUS. Furthermore, our data
suggest that LLPS in the cytoplasm is not a prerequisite
for FUS to exert detrimental effects on cells. The novel
approach that we describe, which allows the identification
of LLPS-specific protein and RNA interactors, should be
applicable to other proteins undergoing LLPS and there-
fore will be a useful method for investigating how LLPS
affects protein/RNA interactions and functions of phase-
separating proteins.
DATA AVAILABILITY
The mass spectrometry data are available via ProteomeX-
change with the identifier PXD015834.
The high-throughput sequencing data are available via
Array Express with the accession number E-MTAB-8456.
Flow Cytometry data are available via FlowRepository
with the identifier FR-FCM-Z35F.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We thank, Muriel Fragnière, Sabrina Schenk and Tosso
Leeb of the Next Generation Sequencing platform (Univer-
sity of Bern) for technical advice and library preparation,
George Chennell of the Wohl Cellular Imaging Centre at
King’s College London (including the Nikon Ti-E eclipse
microscope funded by Alzheimer’s Research UK; ARUK-
EG2013B-1) for technical support as well as Sophie Marie-
Pierre Braga, Anne-Christine Uldry and Manfred Heller of
the Proteomics Mass Spectrometry Core Facility (Univer-
sity of Bern) for technical advice and sample processing. We







niversitaetsbibliothek Bern user on 06 August 2021
Nucleic Acids Research, 2021, Vol. 49, No. 13 7729
Conde de Almeida de Sousa Furtado and Claudia Abou-
Ajram for their excellent technical and organizational sup-
port.
FUNDING
This research project and related results were made possible
with the support of the NOMIS Foundation [to M.D.R.];
UK Dementia Research Institute which receives its fund-
ing from DRI Ltd, funded by the UK Medical Research
Council, Alzheimer’s Society and Alzheimer’s Research UK
[to M.D.R.]; Medical Research Council [MR/S025898/1
to M.D.R. and A.D.]; Motor Neurone Disease Associa-
tion [867-791 to A.D.]; NCCR RNA and Disease funded
by the Swiss National Science Foundation [to M.D.R. and
O.M.]; Deutsche Forschungsgemeinschaft (DFG) within
Emmy Noether Grants [DO1804/1-1 and 1-2 to D.D.]; Mu-
nich Cluster for Systems Neurology [EXC2145 SyNergy –
ID 390857198 to D.D., SPP2191 - ID 402723784 to D.D.].
Funding for open access charge: UK Dementia Research
Institute/Medical Research Council.
Conflict of interest statement. None declared.
REFERENCES
1. Alberti,S. and Carra,S. (2018) Quality control of membraneless
organelles. J. Mol. Biol., 430, 4711–4729.
2. Boeynaems,S., Alberti,S., Fawzi,N.L., Mittag,T., Polymenidou,M.,
Rousseau,F., Schymkowitz,J., Shorter,J., Wolozin,B., Van Den
Bosch,L. et al. (2018) Protein phase separation: a new phase in cell
biology. Trends Cell Biol., 28, 420–435.
3. Alberti,S. and Dormann,D. (2019) Liquid-liquid phase separation
in disease. Annu. Rev. Genet., 53, 171–194.
4. Patel,A., Lee,H.O., Jawerth,L., Maharana,S., Jahnel,M., Hein,M.Y.,
Stoynov,S., Mahamid,J., Saha,S., Franzmann,T.M. et al. (2015) A
liquid-to-solid phase transition of the ALS protein FUS accelerated
by disease mutation. Cell, 162, 1066–1077.
5. Kato,M., Han,T.W., Xie,S., Shi,K., Du,X., Wu,L.C., Mirzaei,H.,
Goldsmith,E.J., Longgood,J., Pei,J et al. (2012) Cell-free formation
of RNA granules: low complexity sequence domains form dynamic
fibers within hydrogels. Cell, 149, 753–767.
6. Schwartz,J.C., Wang,X., Podell,E.R. and Cech,T.R. (2013) RNA
seeds higher-order assembly of FUS protein. Cell Rep., 5, 918–925.
7. Murray,D.T., Kato,M., Lin,Y., Thurber,K.R., Hung,I.,
McKnight,S.L. and Tycko,R. (2017) Structure of FUS protein fibrils
and its relevance to self-assembly and phase separation of
low-complexity domains. Cell, 171, 615–627.
8. Monahan,Z., Ryan,V.H., Janke,A.M., Burke,K.A., Rhoads,S.N.,
Zerze,G.H., Meally,R., Dignon,G.L., Conicella,A.E., Zheng,W.
et al. (2017) Phosphorylation of the FUS low-complexity domain
disrupts phase separation, aggregation, and toxicity. EMBO J., 36,
2951–2967.
9. Hofweber,M., Hutten,S., Bourgeois,B., Spreitzer,E.,
Niedner-Boblenz,A., Schifferer,M., Ruepp,M.-D., Simons,M.,
Niessing,D., Madl,T. et al. (2018) Phase separation of FUS is
suppressed by its nuclear import receptor and arginine methylation.
Cell, 173, 706–719.
10. Kang,J., Lim,L., Lu,Y. and Song,J. (2019) A unified mechanism for
LLPS of ALS/FTLD-causing FUS as well as its modulation by
ATP and oligonucleic acids. PLoS Biol., 17, e3000327.
11. Raczynska,K.D., Ruepp,M.D., Brzek,A., Reber,S., Romeo,V.,
Rindlisbacher,B., Heller,M., Szweykowska-Kulinska,Z.,
Jarmolowski,A. and Schumperli,D. (2015) FUS/TLS contributes to
replication-dependent histone gene expression by interaction with
U7 snRNPs and histone-specific transcription factors. Nucleic Acids
Res., 43, 9711–9728.
12. Reber,S., Stettler,J., Filosa,G., Colombo,M., Jutzi,D., Lenzken,S.C.,
Schweingruber,C., Bruggmann,R., Bachi,A., Barabino,S.M. et al.
(2016) Minor intron splicing is regulated by FUS and affected by
ALS-associated FUS mutants. EMBO J., 35, 1504–1521.
13. Schwartz,J.C., Ebmeier,C.C., Podell,E.R., Heimiller,J., Taatjes,D.J.
and Cech,T.R. (2012) FUS binds the CTD of RNA polymerase II
and regulates its phosphorylation at Ser2. Genes Dev., 26,
2690–2695.
14. Meissner,M., Lopato,S., Gotzmann,J., Sauermann,G. and Barta,A.
(2003) Proto-oncoprotein tls/fus is associated to the nuclear matrix
and complexed with splicing factors ptb, srm160, and sr proteins.
Exp. Cell Res., 283, 184–195.
15. Yu,Y. and Reed,R. (2015) FUS functions in coupling transcription
to splicing by mediating an interaction between RNAP II and U1
snRNP. Proc. Natl. Acad. Sci. U.S.A., 112, 8608–8613.
16. Zhang,T., Wu,Y.-C., Mullane,P., Ji,Y.J., Liu,H., He,L., Arora,A.,
Hwang,H.-Y., Alessi,A.F., Niaki,A.G. et al. (2018) FUS Regulates
Activity of MicroRNA-Mediated Gene Silencing. Mol. Cell, 69,
787–801.
17. Kwiatkowski,T.J., Bosco,D.A., Leclerc,A.L., Tamrazian,E.,
Vanderburg,C.R., Russ,C., Davis,A., Gilchrist,J., Kasarskis,E.J.,
Munsat,T et al. (2009) Mutations in the FUS/TLS gene on
chromosome 16 cause familial amyotrophic lateral sclerosis. Science,
323, 1205–1208.
18. Vance,C., Rogelj,B., Hortobagyi,T., De Vos,K.J., Nishimura,A.L.,
Sreedharan,J., Hu,X., Smith,B., Ruddy,D., Wright,P. et al. (2009)
Mutations in FUS, an RNA processing protein, cause familial
amyotrophic lateral sclerosis type 6. Science, 323, 1208–1211.
19. Cleveland,D.W. and Rothstein,J.D. (2001) From Charcot to Lou
Gehrig: deciphering selective motor neuron death in ALS. Nat. Rev.
Neurosci., 2, 806–819.
20. Ling,S.C., Polymenidou,M. and Cleveland,D.W. (2013) Converging
mechanisms in ALS and FTD: disrupted RNA and protein
homeostasis. Neuron, 79, 416–438.
21. Dormann,D., Rodde,R., Edbauer,D., Bentmann,E., Fischer,I.,
Hruscha,A., Than,M.E., Mackenzie,I.R.A., Capell,A., Schmid,B.
et al. (2010) ALS-associated fused in sarcoma (FUS) mutations
disrupt Transportin-mediated nuclear import. EMBO J., 29,
2841–2857.
22. Sharma,A., Lyashchenko,A.K., Lu,L., Nasrabady,S.E.,
Elmaleh,M., Mendelsohn,M., Nemes,A., Tapia,J.C., Mentis,G.Z.
and Shneider,N.A. (2016) ALS-associated mutant FUS induces
selective motor neuron degeneration through toxic gain of function.
Nat. Commun., 7, 10465.
23. Scekic-Zahirovic,J., Sendscheid,O., El Oussini,H., Jambeau,M.,
Sun,Y., Mersmann,S., Wagner,M., Dieterlé,S., Sinniger,J.,
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